Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Новый представитель класса статинов – крестор: возможности в лечении больных с метаболическим синдромом - Журнал Системные Гипертензии №1 (2006)
Новый представитель класса статинов – крестор: возможности в лечении больных с метаболическим синдромом
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998; 81: 66B–69B.
2. Goldschmidt MG, Barret-Conner E, Edelstein SL et al. Dyslipidaemia and ischaemic heart disease mortality among men and women with diabetes. Circulation 1994; 89: 991–7.
3. Scandinavian Simvastatin Survival Study Group: Randomaised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9.
4. Appel S, Rufenacht T. Lack of Interaction Between Fluvastatin and Oral Hypoglycemia Agents in Healthy Subjects and in Patients with Non-Insulin-Dependent Diabetes Mellitus. Am J Cardiol 1995; 76: 29A–32A.
5. Rackley CE. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease. Clin Cardiol 1996; 19: 683–9.
6. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7B–12B.
7. Jones P, Davidson M, Stein E et al. Comparison of efficacy of rosuvastatin versus atorvastatin, simvastatin and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19: 557–66.
8. Schuster H, Fox JC. Investigating cardiovascular risk reduction – the Rosuvastatin GALAXY Programme. Expert Opin Pharmacother 2004; 5 (5): 1187–200.
9. Balantyne CM, Stein EA, Paoletti R et al. Efficacy of Rosuvastatin 10 mg in patients with the Metabolic Syndrome. Am J Cardiol 2003; 91 (suppl.): 25C–28C.
10. Schuster H, Barter PJ, Stender S et al. For the MERCURY I study group: Effects of switching statins on achievement of lipid goal: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study. Am Heart Journal 2004; 147: 705–12.
2. Goldschmidt MG, Barret-Conner E, Edelstein SL et al. Dyslipidaemia and ischaemic heart disease mortality among men and women with diabetes. Circulation 1994; 89: 991–7.
3. Scandinavian Simvastatin Survival Study Group: Randomaised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9.
4. Appel S, Rufenacht T. Lack of Interaction Between Fluvastatin and Oral Hypoglycemia Agents in Healthy Subjects and in Patients with Non-Insulin-Dependent Diabetes Mellitus. Am J Cardiol 1995; 76: 29A–32A.
5. Rackley CE. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease. Clin Cardiol 1996; 19: 683–9.
6. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7B–12B.
7. Jones P, Davidson M, Stein E et al. Comparison of efficacy of rosuvastatin versus atorvastatin, simvastatin and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19: 557–66.
8. Schuster H, Fox JC. Investigating cardiovascular risk reduction – the Rosuvastatin GALAXY Programme. Expert Opin Pharmacother 2004; 5 (5): 1187–200.
9. Balantyne CM, Stein EA, Paoletti R et al. Efficacy of Rosuvastatin 10 mg in patients with the Metabolic Syndrome. Am J Cardiol 2003; 91 (suppl.): 25C–28C.
10. Schuster H, Barter PJ, Stender S et al. For the MERCURY I study group: Effects of switching statins on achievement of lipid goal: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study. Am Heart Journal 2004; 147: 705–12.
Авторы
И.Е.Чазова, В.Б.Мычка, К.М.Мамырбаева, В.П.Масенко, Н.В.Флегонтова, В.Б.Сергиенко
Российский кардиологический научно-производственный комплекс Росздрава,
Институт кардиологии им. А.Л.Мясникова, Москва
Российский кардиологический научно-производственный комплекс Росздрава,
Институт кардиологии им. А.Л.Мясникова, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.